Vaccines
The development of Ebola vaccine was initiated in 1980s, focused on attempts to inactivate the virus. Since then, a number of vaccines have been tested in rodents and non-human primates, including inactivated virus, DNA vaccines, virus-like particles and vaccines based on recombinant viral vectors 68. Some animal models have been developed to study the pathogenesis of Ebola virus infection and assess the efficacy of various vaccine candidates including mice, guinea pigs and other non-human primates. Rodent models do not always predict vaccine efficacy in non-human primates and employ Ebola virus- adaptive strains. Non-human primates usually rhesus and
The development of Ebola vaccine was initiated in 1980s, focused on attempts to inactivate the virus. Since then, a number of vaccines have been tested in rodents and non-human primates, including inactivated virus, DNA vaccines, virus-like particles and vaccines based on recombinant viral vectors 68. Some animal models have been developed to study the pathogenesis of Ebola virus infection and assess the efficacy of various vaccine candidates including mice, guinea pigs and other non-human primates. Rodent models do not always predict vaccine efficacy in non-human primates and employ Ebola virus- adaptive strains. Non-human primates usually rhesus and